Exacerbations of Idiopathic Systemic Capillary Leak Syndrome following BNT162b2 mRNA COVID-19 Vaccine (Pfizer-BioNTech)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Exacerbations of Idiopathic Systemic Capillary Leak Syndrome following BNT162b2 mRNA COVID-19 Vaccine (Pfizer-BioNTech)

Published:2023-07-01 Issue:13 Volume:62 Page:2013-2017
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Akiyama Yutaro¹,Inagaki Takeshi²,Morioka Shinichiro¹,Kusano Eiji³,Ohmagari Norio¹

Affiliation:

1. Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan

2. Department of General Medicine, National Center for Global Health and Medicine, Japan

3. Department of Diabetes, Metabolism and Kidney Disease, Edogawa Hospital, Japan

Publisher

Japanese Society of Internal Medicine

Subject

General Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/62/13/62_1682-23/_pdf

Reference30 articles.

1. 1. Clarkson B, Thompson D, Horwith M, Luckey EH. Cyclical edema and shock due to increased capillary permeability. Am J Med 29: 193-216, 1960.

2. 2. Atkinson JP, Waldmann TA, Stein SF, et al. Systemic capillary leak syndrome and monoclonal IgG gammopathy; studies in a sixth patient and a review of the literature. Medicine (Baltimore) 56: 225-239, 1977.

3. 3. Kapoor P, Greipp PT, Schaefer EW, et al. Idiopathic systemic capillary leak syndrome (Clarkson's disease): the Mayo Clinic experience. Mayo Clin Proc 85: 905-912, 2010.

4. 4. Siddall E, Khatri M, Radhakrishnan J. Capillary leak syndrome: etiologies, pathophysiology, and management. Kidney Int 92: 37-46, 2017.

5. 5. Orucevic A, Lala PK. Role of nitric oxide in IL-2 therapy-induced capillary leak syndrome. Cancer Metastasis Rev 17: 127-142, 1998.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The systemic capillary leak syndrome following COVID-19 vaccine;Human Vaccines & Immunotherapeutics;2024-08-22

2. The mRNA-LNP vaccines – the good, the bad and the ugly?;Frontiers in Immunology;2024-02-08

3. Tozinameran;Reactions Weekly;2023-07-29

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3